Evidence map›Paper›PMID 27328812›Full record

ArticleHuman mutation2016

A Role for the Chromatin-Remodeling Factor BAZ1A in Neurodevelopment.

Ammar Zaghlool, Jonatan Halvardson, Jin J Zhao, Mitra Etemadikhah, Antonia Kalushkova, Katarzyna Konska, Helena Jernberg-Wiklund, Ann-Charlotte Thuresson, Lars Feuk

Open access · hybridAbstract read
In one paragraph

Article in Human mutation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ammar ZaghloolDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Jonatan HalvardsonDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Jin J ZhaoDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Mitra EtemadikhahDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Antonia KalushkovaDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Katarzyna KonskaDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Helena Jernberg-WiklundDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Ann-Charlotte ThuressonDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Lars FeukDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Science for Life Laboratory · SEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chromatin-remodeling factors are required for a wide range of cellular and biological processes including development and cognition, mainly by regulating gene expression. As these functions would predict, deregulation of chromatin-remodeling factors causes various disease syndromes, including neurodevelopmental disorders. Recent reports have linked mutations in several genes coding for chromatin-remodeling factors to intellectual disability (ID). Here, we used exome sequencing and identified a nonsynonymous de novo mutation in BAZ1A (NM_182648.2:c.4043T > G, p.Phe1348Cys), encoding the ATP-utilizing chromatin assembly and remodeling factor 1 (ACF1), in a patient with unexplained ID. ACF1 has been previously reported to bind to the promoter of the vitamin D receptor (VDR)-regulated genes and suppress their expression. Our results show that the patient displays decreased binding of ACF1 to the promoter of the VDR-regulated gene CYP24A1. Using RNA sequencing, we find that the mutation affects the expression of genes involved in several pathways including vitamin D metabolism, Wnt signaling and synaptic formation. RNA sequencing of BAZ1A knockdown cells and Baz1a knockout mice revealed that BAZ1A carry out distinctive functions in different tissues. We also demonstrate that BAZ1A depletion influence the expression of genes important for nervous system development and function. Our data point to an important role for BAZ1A in neurodevelopment, and highlight a possible link for BAZ1A to ID.

Indexed as

Amino Acid SubstitutionAnimalsBromodomain Containing ProteinsCell LineChromosomal Proteins, Non-HistoneExomeGene Regulatory NetworksHumansIntellectual DisabilityMiceNervous SystemPromoter Regions, GeneticReceptors, CalcitriolSequence Analysis, DNASequence Analysis, RNASynaptic PotentialsBAZ1A protein, humanBromodomain Containing ProteinsChromosomal Proteins, Non-HistoneReceptors, CalcitriolTranscription FactorsVDR protein, humanACF1BAZ1ACYP24A1epilepsyintellectual disabilityneurodevelopmentvitamin D metabolismWnt signaling

Identifiers

PMID27328812
PMCPMC6681169
OpenAlexW2461543904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.